Pentoxifylline in the management of thyroid eye disease

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pentoxifylline (Ptx) (1-/5-oxohexyl)-3,7-dimethylxantine) has been widely used for the treatment of chronic occlusive arterial disease because of its rheological action. The effectiveness of this drug has been attributed to its influence on erythrocyte deformability, platelet reactivity and plasma viscosity, and prostacycline release (1). Like other methylxanthines, Ptx inhibits phosphodiesterase, resulting in a significant increase of intracellular cyclic adenosine monophosphate (cAMP), which is known to modulate a number of cellular immune functions (2,3). It has been reported that Ptx is able to inhibit inflammatory processes including phagocytosis and superoxide anion and nitric oxide (NO) production by polymorphonuclear granulocytes and monocytes (4,5). This drug has also been reported to affect T lymphocytes by modulating production of various cytokines involved in immune and autoimmune reactions (6-9). Recently, the immunomodulating effects of Ptx were investigated in a randomized double-blind study comparing Ptx with placebo in 140 patients receiving cadaveric kidney grafts under cyclosporine and prednisolone treatment. Ptx weakened the consequences of rejection on graft survival and this phenomenon was mediated by reduction of tumor necrosis factor a (TNF-a) in sera of patients receiving transplants (10-12). Furthermore, Ptx influenced cytokine-induced fibroblast proliferation. Ptx exerted a robust inhibitory effect on fibroblast proliferation, extracellular matrix synthesis, and myofibroblast differentiation (13).

Original languageEnglish
Title of host publicationThyroid Eye Disease
Subtitle of host publicationDiagnosis and Treatment
PublisherCRC Press
Pages441-447
Number of pages7
ISBN (Electronic)9780824743871
ISBN (Print)9780824707712
Publication statusPublished - Jan 1 2002

Fingerprint

Pentoxifylline
Eye Diseases
Thyroid Diseases
Fibroblasts
Erythrocyte Deformability
Cytokines
Transplants
Arterial Occlusive Diseases
Myofibroblasts
Phosphoric Diester Hydrolases
Graft Survival
Prednisolone
Phagocytosis
Double-Blind Method
Granulocytes
Viscosity
Superoxides
Pharmaceutical Preparations
Cyclic AMP
Cyclosporine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Balázs, C. (2002). Pentoxifylline in the management of thyroid eye disease. In Thyroid Eye Disease: Diagnosis and Treatment (pp. 441-447). CRC Press.

Pentoxifylline in the management of thyroid eye disease. / Balázs, C.

Thyroid Eye Disease: Diagnosis and Treatment. CRC Press, 2002. p. 441-447.

Research output: Chapter in Book/Report/Conference proceedingChapter

Balázs, C 2002, Pentoxifylline in the management of thyroid eye disease. in Thyroid Eye Disease: Diagnosis and Treatment. CRC Press, pp. 441-447.
Balázs C. Pentoxifylline in the management of thyroid eye disease. In Thyroid Eye Disease: Diagnosis and Treatment. CRC Press. 2002. p. 441-447
Balázs, C. / Pentoxifylline in the management of thyroid eye disease. Thyroid Eye Disease: Diagnosis and Treatment. CRC Press, 2002. pp. 441-447
@inbook{aae972ee7d4e4212aaae1be0482d6acb,
title = "Pentoxifylline in the management of thyroid eye disease",
abstract = "Pentoxifylline (Ptx) (1-/5-oxohexyl)-3,7-dimethylxantine) has been widely used for the treatment of chronic occlusive arterial disease because of its rheological action. The effectiveness of this drug has been attributed to its influence on erythrocyte deformability, platelet reactivity and plasma viscosity, and prostacycline release (1). Like other methylxanthines, Ptx inhibits phosphodiesterase, resulting in a significant increase of intracellular cyclic adenosine monophosphate (cAMP), which is known to modulate a number of cellular immune functions (2,3). It has been reported that Ptx is able to inhibit inflammatory processes including phagocytosis and superoxide anion and nitric oxide (NO) production by polymorphonuclear granulocytes and monocytes (4,5). This drug has also been reported to affect T lymphocytes by modulating production of various cytokines involved in immune and autoimmune reactions (6-9). Recently, the immunomodulating effects of Ptx were investigated in a randomized double-blind study comparing Ptx with placebo in 140 patients receiving cadaveric kidney grafts under cyclosporine and prednisolone treatment. Ptx weakened the consequences of rejection on graft survival and this phenomenon was mediated by reduction of tumor necrosis factor a (TNF-a) in sera of patients receiving transplants (10-12). Furthermore, Ptx influenced cytokine-induced fibroblast proliferation. Ptx exerted a robust inhibitory effect on fibroblast proliferation, extracellular matrix synthesis, and myofibroblast differentiation (13).",
author = "C. Bal{\'a}zs",
year = "2002",
month = "1",
day = "1",
language = "English",
isbn = "9780824707712",
pages = "441--447",
booktitle = "Thyroid Eye Disease",
publisher = "CRC Press",

}

TY - CHAP

T1 - Pentoxifylline in the management of thyroid eye disease

AU - Balázs, C.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Pentoxifylline (Ptx) (1-/5-oxohexyl)-3,7-dimethylxantine) has been widely used for the treatment of chronic occlusive arterial disease because of its rheological action. The effectiveness of this drug has been attributed to its influence on erythrocyte deformability, platelet reactivity and plasma viscosity, and prostacycline release (1). Like other methylxanthines, Ptx inhibits phosphodiesterase, resulting in a significant increase of intracellular cyclic adenosine monophosphate (cAMP), which is known to modulate a number of cellular immune functions (2,3). It has been reported that Ptx is able to inhibit inflammatory processes including phagocytosis and superoxide anion and nitric oxide (NO) production by polymorphonuclear granulocytes and monocytes (4,5). This drug has also been reported to affect T lymphocytes by modulating production of various cytokines involved in immune and autoimmune reactions (6-9). Recently, the immunomodulating effects of Ptx were investigated in a randomized double-blind study comparing Ptx with placebo in 140 patients receiving cadaveric kidney grafts under cyclosporine and prednisolone treatment. Ptx weakened the consequences of rejection on graft survival and this phenomenon was mediated by reduction of tumor necrosis factor a (TNF-a) in sera of patients receiving transplants (10-12). Furthermore, Ptx influenced cytokine-induced fibroblast proliferation. Ptx exerted a robust inhibitory effect on fibroblast proliferation, extracellular matrix synthesis, and myofibroblast differentiation (13).

AB - Pentoxifylline (Ptx) (1-/5-oxohexyl)-3,7-dimethylxantine) has been widely used for the treatment of chronic occlusive arterial disease because of its rheological action. The effectiveness of this drug has been attributed to its influence on erythrocyte deformability, platelet reactivity and plasma viscosity, and prostacycline release (1). Like other methylxanthines, Ptx inhibits phosphodiesterase, resulting in a significant increase of intracellular cyclic adenosine monophosphate (cAMP), which is known to modulate a number of cellular immune functions (2,3). It has been reported that Ptx is able to inhibit inflammatory processes including phagocytosis and superoxide anion and nitric oxide (NO) production by polymorphonuclear granulocytes and monocytes (4,5). This drug has also been reported to affect T lymphocytes by modulating production of various cytokines involved in immune and autoimmune reactions (6-9). Recently, the immunomodulating effects of Ptx were investigated in a randomized double-blind study comparing Ptx with placebo in 140 patients receiving cadaveric kidney grafts under cyclosporine and prednisolone treatment. Ptx weakened the consequences of rejection on graft survival and this phenomenon was mediated by reduction of tumor necrosis factor a (TNF-a) in sera of patients receiving transplants (10-12). Furthermore, Ptx influenced cytokine-induced fibroblast proliferation. Ptx exerted a robust inhibitory effect on fibroblast proliferation, extracellular matrix synthesis, and myofibroblast differentiation (13).

UR - http://www.scopus.com/inward/record.url?scp=85056966038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056966038&partnerID=8YFLogxK

M3 - Chapter

SN - 9780824707712

SP - 441

EP - 447

BT - Thyroid Eye Disease

PB - CRC Press

ER -